Wells Fargo & Company Hcw Biologics Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.1 - $1.77 $3 - $5	3 Added 2.17%	141 $0
Q4 2023 Feb 09, 2024	BUY	$0.92 - $2.14 $6 - $14	7 Added 5.34%	138 $0
Q3 2023 Nov 13, 2023	BUY	$1.75 - $2.31 $52 - $69	30 Added 29.7%	131 $0
Q2 2023 Aug 15, 2023	BUY	$1.35 - $2.3 $5 - $9	4 Added 4.12%	101 $0
Q1 2023 May 12, 2023	BUY	$1.12 - $2.19 $2 - $4	2 Added 2.11%	97 $0
Q4 2022 Feb 13, 2023	BUY	$1.84 - $2.36 $3 - $4	2 Added 2.15%	95 $0
Q3 2022 Nov 14, 2022	BUY	$2.13 - $2.74 $95 - $123	45 Added 93.75%	93 $0
Q2 2022 Aug 12, 2022	BUY	$1.96 - $3.17 $7 - $12	4 Added 9.09%	48 $0
Q3 2021 Nov 15, 2021	BUY	$3.14 - $6.3 $138 - $277	44 New	44 $0

1.16M

Ticker HCWB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,833,100
Market Cap $14.7M
Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.